Earnings ·
Maravai reports Q3 revenue of $45.9M, raises full-year guidance to $216M
MRVIMaravai Lifesciences Holdings, Inc.
Maravai LifeSciences reported third-quarter 2026 total revenue of $45.9 million, a 10% increase from the prior year period, driven by 12% growth in its TriLink segment and 8% growth at Cygnus. The company posted a net loss of $(24.0) million and Adjusted EBITDA of $5.8 million for the quarter. Management raised full-year 2026 revenue guidance to a range of $212.0 million to $216.0 million, up from the previous estimate, and increased Adjusted EBITDA guidance to $40.0 million–$42.0 million. Maravai is a global provider of life science reagents and services to researchers and biotech innovators.